Nonalcoholic fatty liver disease: A potential consequence of tumor necrosis factor-inhibitor therapy

Linda A. Feagins, Avegail Flores, Cristina Arriens, Christina Park, Terri Crook, Andreas Reimold, Geri Brown

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction Although tumor necrosis factor inhibitors (TNFi) might be expected to protect against nonalcoholic fatty liver disease (NAFLD), we have seen patients who appeared to develop NAFLD during TNFi treatment. We aimed to explore risk factors for this TNFi complication in a case-control study. Methods We reviewed clinic records at our VA hospital to identify patients with inflammatory diseases who developed aminotransferase elevations during TNFi therapy and who had liver biopsies showing NAFLD. These patients were matched with patients in each of three control groups: (i) inflammatory disease controls: patients on TNFi treatment with normal aminotransferase levels, (ii) nonalcoholic steatohepatitis (NASH) controls: patients with biopsy-proven NASH with no other inflammatory disease, and (iii) healthy controls. Genotyping was performed for PNPLA3, a gene predisposing to NASH. Results We identified eight cases (five steatohepatitis, three steatosis); elevated aminotransferase levels were first observed 1-63 months into TNFi therapy (average 12 months). TNFi therapy was stopped in five patients, whose aminotransferase levels then normalized within 2-8 months. There were no significant differences between cases and inflammatory disease controls in the frequency of features of metabolic syndrome. Cases had more methotrexate exposure than inflammatory controls (50 vs. 12.5%, P=0.28). PNPLA3 genotyping revealed mutations in 75% of cases, 38% of inflammatory controls, 88% of NASH controls, and 63% of healthy controls (P=NS). Conclusion Our findings suggest that NAFLD can be a side effect of TNFi therapy, and that methotrexate exposure and PNPLA3 gene mutations might be risk factors. Further studies are needed to determine how TNFi causes NAFLD and to confirm these risk factors.

Original languageEnglish (US)
Pages (from-to)1154-1160
Number of pages7
JournalEuropean Journal of Gastroenterology and Hepatology
Volume27
Issue number10
DOIs
StatePublished - Sep 18 2015

Fingerprint

Tumor Necrosis Factor-alpha
Transaminases
Therapeutics
Methotrexate
Implosive Therapy
Biopsy
Non-alcoholic Fatty Liver Disease
Mutation
Fatty Liver
Genes
Case-Control Studies
Control Groups
Liver

Keywords

  • inflammatory diseases
  • nonalcoholic steatohepatitis
  • PNPLA3
  • tumor necrosis factor inhibitor

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Nonalcoholic fatty liver disease : A potential consequence of tumor necrosis factor-inhibitor therapy. / Feagins, Linda A.; Flores, Avegail; Arriens, Cristina; Park, Christina; Crook, Terri; Reimold, Andreas; Brown, Geri.

In: European Journal of Gastroenterology and Hepatology, Vol. 27, No. 10, 18.09.2015, p. 1154-1160.

Research output: Contribution to journalArticle

Feagins, Linda A. ; Flores, Avegail ; Arriens, Cristina ; Park, Christina ; Crook, Terri ; Reimold, Andreas ; Brown, Geri. / Nonalcoholic fatty liver disease : A potential consequence of tumor necrosis factor-inhibitor therapy. In: European Journal of Gastroenterology and Hepatology. 2015 ; Vol. 27, No. 10. pp. 1154-1160.
@article{04d7d5e7923a48cbb40ae471f2f45245,
title = "Nonalcoholic fatty liver disease: A potential consequence of tumor necrosis factor-inhibitor therapy",
abstract = "Introduction Although tumor necrosis factor inhibitors (TNFi) might be expected to protect against nonalcoholic fatty liver disease (NAFLD), we have seen patients who appeared to develop NAFLD during TNFi treatment. We aimed to explore risk factors for this TNFi complication in a case-control study. Methods We reviewed clinic records at our VA hospital to identify patients with inflammatory diseases who developed aminotransferase elevations during TNFi therapy and who had liver biopsies showing NAFLD. These patients were matched with patients in each of three control groups: (i) inflammatory disease controls: patients on TNFi treatment with normal aminotransferase levels, (ii) nonalcoholic steatohepatitis (NASH) controls: patients with biopsy-proven NASH with no other inflammatory disease, and (iii) healthy controls. Genotyping was performed for PNPLA3, a gene predisposing to NASH. Results We identified eight cases (five steatohepatitis, three steatosis); elevated aminotransferase levels were first observed 1-63 months into TNFi therapy (average 12 months). TNFi therapy was stopped in five patients, whose aminotransferase levels then normalized within 2-8 months. There were no significant differences between cases and inflammatory disease controls in the frequency of features of metabolic syndrome. Cases had more methotrexate exposure than inflammatory controls (50 vs. 12.5{\%}, P=0.28). PNPLA3 genotyping revealed mutations in 75{\%} of cases, 38{\%} of inflammatory controls, 88{\%} of NASH controls, and 63{\%} of healthy controls (P=NS). Conclusion Our findings suggest that NAFLD can be a side effect of TNFi therapy, and that methotrexate exposure and PNPLA3 gene mutations might be risk factors. Further studies are needed to determine how TNFi causes NAFLD and to confirm these risk factors.",
keywords = "inflammatory diseases, nonalcoholic steatohepatitis, PNPLA3, tumor necrosis factor inhibitor",
author = "Feagins, {Linda A.} and Avegail Flores and Cristina Arriens and Christina Park and Terri Crook and Andreas Reimold and Geri Brown",
year = "2015",
month = "9",
day = "18",
doi = "10.1097/MEG.0000000000000421",
language = "English (US)",
volume = "27",
pages = "1154--1160",
journal = "European Journal of Gastroenterology and Hepatology",
issn = "0954-691X",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Nonalcoholic fatty liver disease

T2 - A potential consequence of tumor necrosis factor-inhibitor therapy

AU - Feagins, Linda A.

AU - Flores, Avegail

AU - Arriens, Cristina

AU - Park, Christina

AU - Crook, Terri

AU - Reimold, Andreas

AU - Brown, Geri

PY - 2015/9/18

Y1 - 2015/9/18

N2 - Introduction Although tumor necrosis factor inhibitors (TNFi) might be expected to protect against nonalcoholic fatty liver disease (NAFLD), we have seen patients who appeared to develop NAFLD during TNFi treatment. We aimed to explore risk factors for this TNFi complication in a case-control study. Methods We reviewed clinic records at our VA hospital to identify patients with inflammatory diseases who developed aminotransferase elevations during TNFi therapy and who had liver biopsies showing NAFLD. These patients were matched with patients in each of three control groups: (i) inflammatory disease controls: patients on TNFi treatment with normal aminotransferase levels, (ii) nonalcoholic steatohepatitis (NASH) controls: patients with biopsy-proven NASH with no other inflammatory disease, and (iii) healthy controls. Genotyping was performed for PNPLA3, a gene predisposing to NASH. Results We identified eight cases (five steatohepatitis, three steatosis); elevated aminotransferase levels were first observed 1-63 months into TNFi therapy (average 12 months). TNFi therapy was stopped in five patients, whose aminotransferase levels then normalized within 2-8 months. There were no significant differences between cases and inflammatory disease controls in the frequency of features of metabolic syndrome. Cases had more methotrexate exposure than inflammatory controls (50 vs. 12.5%, P=0.28). PNPLA3 genotyping revealed mutations in 75% of cases, 38% of inflammatory controls, 88% of NASH controls, and 63% of healthy controls (P=NS). Conclusion Our findings suggest that NAFLD can be a side effect of TNFi therapy, and that methotrexate exposure and PNPLA3 gene mutations might be risk factors. Further studies are needed to determine how TNFi causes NAFLD and to confirm these risk factors.

AB - Introduction Although tumor necrosis factor inhibitors (TNFi) might be expected to protect against nonalcoholic fatty liver disease (NAFLD), we have seen patients who appeared to develop NAFLD during TNFi treatment. We aimed to explore risk factors for this TNFi complication in a case-control study. Methods We reviewed clinic records at our VA hospital to identify patients with inflammatory diseases who developed aminotransferase elevations during TNFi therapy and who had liver biopsies showing NAFLD. These patients were matched with patients in each of three control groups: (i) inflammatory disease controls: patients on TNFi treatment with normal aminotransferase levels, (ii) nonalcoholic steatohepatitis (NASH) controls: patients with biopsy-proven NASH with no other inflammatory disease, and (iii) healthy controls. Genotyping was performed for PNPLA3, a gene predisposing to NASH. Results We identified eight cases (five steatohepatitis, three steatosis); elevated aminotransferase levels were first observed 1-63 months into TNFi therapy (average 12 months). TNFi therapy was stopped in five patients, whose aminotransferase levels then normalized within 2-8 months. There were no significant differences between cases and inflammatory disease controls in the frequency of features of metabolic syndrome. Cases had more methotrexate exposure than inflammatory controls (50 vs. 12.5%, P=0.28). PNPLA3 genotyping revealed mutations in 75% of cases, 38% of inflammatory controls, 88% of NASH controls, and 63% of healthy controls (P=NS). Conclusion Our findings suggest that NAFLD can be a side effect of TNFi therapy, and that methotrexate exposure and PNPLA3 gene mutations might be risk factors. Further studies are needed to determine how TNFi causes NAFLD and to confirm these risk factors.

KW - inflammatory diseases

KW - nonalcoholic steatohepatitis

KW - PNPLA3

KW - tumor necrosis factor inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84942040926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942040926&partnerID=8YFLogxK

U2 - 10.1097/MEG.0000000000000421

DO - 10.1097/MEG.0000000000000421

M3 - Article

C2 - 26148245

AN - SCOPUS:84942040926

VL - 27

SP - 1154

EP - 1160

JO - European Journal of Gastroenterology and Hepatology

JF - European Journal of Gastroenterology and Hepatology

SN - 0954-691X

IS - 10

ER -